Madrigal Pharmaceuticals IncMDGL
Price$499.71

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $1.3B+612.8% YoYTTM through 30 Jun 2026
Net Income -$325.1MTTM through 30 Jun 2026
Free Cash Flow -$206.3MTTM through 30 Jun 2026

Margins

Current
Gross Margin91.4%
EBITDA Margin-25.0%
Operating Margin-29.8%
Net Margin-25.3%

Returns

-50.2%ROE
-24.0%ROA

Balance Sheet Health

Debt / Equity0.56x
Current Ratio3.49x
Net Debt-$472.4Mnet cash position
Cash & Equivalents$292.7M

Quality Metrics

Altman Z-Score8.43
Piotroski F-Score5 / 9
FCF Margin-16.1%
Rule of 402.8
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'22'23'24'25
FY2025: $958.4M
Diluted EPS-$11.29TTM
'20'21'22'23'24'25
FY2025: $-12.85

Dividend

No dividend

Capital Allocation

Capex Intensity0.7%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.